Skip to content
drillr.ai

HALO

Halozyme Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$77.09-0.93%

Price as of Jul 20, 2026

HALO news

Halozyme Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

    Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology PR Newswire SAN DIEGO, July 20, 2026 Agreement provides Incyte the rights to develop and commercialize ENHANZE(®) with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") to

    PR Newswire ·

  2. Halozyme Appoints David Ramsay as President Drug Delivery

    Halozyme Appoints David Ramsay as President Drug Delivery PR Newswire SAN DIEGO, June 30, 2026 SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr. Ramsay will have an enterprise-wide, cross-technology mandate, and will be responsible for driving the growth of Halozyme's drug delivery technologies by

    PR Newswire ·

  3. Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

    Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 PR Newswire SAN DIEGO, June 15, 2026 SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Neg

    PR Newswire ·

  4. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

    HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE PR Newswire SAN DIEGO, May 11, 2026 Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026 Total Revenue Increased 42% YOY to $377 million Royalty Revenue Increased 43% YOY to $241 million Reiterating 2026 Financial Guidance Ranges: Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30% Royalty Revenue of $1.130 - $1.170 billion, YOY Growth of 30% -

    PR Newswire ·

  5. Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

    Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”) Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of April, May, and June. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date Details of the per-unit cash distribu

    Business Wire ·

  6. Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Funds (ETFs)

    Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Funds (ETFs) Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETFs for the month March. Unitholders of record of the ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date Details of the per-unit cash distribution amount are as follows: Fund Name Ticker Cash CUSIP ISIN Record Date Payment Exchange Symbol Dis

    Business Wire ·

  7. U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

    U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma PR Newswire SAN DIEGO, March 6, 2026 FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens SAN DIEGO, March 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Ad

    PR Newswire ·

  8. Halozyme to Participate in Upcoming Investor Conferences

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nPngpNSqa&default-theme=true Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Feb. 25, 2026 SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host in

    PR Newswire ·